TearScience, Inc.’s LipiFlow® Treatments a Highlight at American Society of Cataract & Refractive Surgery Congress

MORRISVILLE, N.C.--(BUSINESS WIRE)--TearScience®, Inc., a privately-held medical device company, today announced that its system for evaporative dry eye, which includes the LipiView® Ocular Surface Interferometer and LipiFlow® Thermal Pulsation System, increased in acceptance among eye care physicians as a new standard of care in dry eye this month. Unsolicited demand for more than 30 live, in-booth LipiFlow® treatments was met above the seven demonstrations originally scheduled for the ASCRS•ASOA held in Chicago from April 20-24, 2012. Added requests for personal experience with the LipiFlow® treatment was a clear indicator of the impact that the TearScience® commercial offering made when unveiled for the first time since the U.S. Food and Drug Administration’s clearance for treatment of Meibomian gland dysfunction (MGD) and evaporative dry eye.

Back to news